Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.
BACKGROUND
Vinorelbine was added to carboplatin plus paclitaxel to determine efficacy and toxicity in non-small cell lung cancer (NSCLC) patients with good performance status.


METHODS
Vinorelbine 30 mg/m2 plus paclitaxel 175 mg/m2 plus carboplatin AUC 5 was administered every three weeks for a maximum of 6 cycles.


RESULTS
One out of 37 patients had a complete and 12 a partial remission (35% response rate). Six patients (16%) had disease stabilization and 18 (49%) progressed. Grade III or IV neutropenia occurred in 11 (30%) and febrile neutropenia in 6 (16%) patients. Grade III/IV neuropathy was observed in 6 (16%) patients. The median time to progression was 6 months (95% CI 4.0 - 8.0), and median survival 11 months (95% CI 8.3 - 13.7). One- and two-year survival was 41% (95% CI 24 - 58) and 24% (95% CI 8.7 - 39.1), respectively.


CONCLUSIONS
This triple-chemotherapy combination is feasible. The response rates justify further investigation in similar patient subgroups.
Schmittel
Alexander
A
Department of Medicine III (Hematology, Oncology and Transfusionmedicine), University Medicine of Berlin, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. alexander.schmittel@charite.de
Siehl
Jan Michael
JM
Schulze
Manfred
M
Schulze
Karsten
K
Thiel
Eckhard
E
Keilholz
Ulrich
U
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage*; D015996:Survival Rate; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000077235:Vinorelbine
D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D000077235:Vinorelbine